Moneycontrol PRO
Open App
you are here: HomeNewsIndia

For now, Covaxin likely to be only COVID-19 vaccine available for children of 15-18 years

Also, healthcare and frontline workers and citizens above 60 years of age with comorbidities would be administered the third dose of the same vaccine they had been given before.

December 27, 2021 / 09:13 AM IST
File image of a vial of Covaxin vaccine

File image of a vial of Covaxin vaccine

Bharat Biotech’s Covaxin is likely to be the only COVID-19 vaccine available, for now, for children in the age group of 15-18 years, who will be inoculated from January 3, official sources said.

Also, healthcare and frontline workers and citizens above 60 years of age with comorbidities would be administered the third dose of the same vaccine they had been given before.

Prime Minister Narendra Modi, in a televised address to the nation on Saturday night, announced that vaccination against COVID-19 for children between 15-18 years will start from January 3, while "precaution dose" for healthcare and frontline workers would be administered from January 10.

The decisions came amid rising Covid cases linked to the Omicron variant of the virus. The precaution dose will also be available for citizens above 60 years of age and with comorbidities on the advice of their doctor from January 10 next year as well, the prime minister had said.

"Bharat Biotech’s Covaxin is the only COVID-19 vaccine which will be administered, for now, to children in the age group of 15-18 years who will be inoculated from January 3. The estimated population to be covered in this category is seven to eight crores," an official source said.


COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more

The source said that Zydus Cadila’s vaccine ZyCoV-D has not yet been introduced in the country’s inoculation programme, even for adults, though it had received emergency use authorisation from the drug regulator on August 20, making it the first vaccine that could be administered in the age group of 12-18 years in the country.

The indigenously developed ZyCoV-D is the world’s first DNA-based needle-free COVID-19 vaccine. The gap between the second and third dose of COVID-19 vaccine, which is being termed as "precaution dose", is likely to be nine to 12 months.

Necessary modifications are being done on the CoWIN portal to register the new category of vaccination. The Drugs Controller General of India (DCGI) granted emergency use authorisation to indigenously-developed Covaxin for children above 12 years with certain conditions on Friday.

More than 61 per cent of India’s adult population has received both doses of the vaccine. Similarly, about 90 per cent of the adult population has received the first dose of Covid vaccine.

The cumulative COVID-19 vaccine doses administered in the country has exceeded 141 crore, according to the health ministry. A stock of four to five crore vaccine doses of Covaxin are available with states and union territories.
first published: Dec 27, 2021 09:14 am
ISO 27001 - BSI Assurance Mark